FindTrial
Sign In

Stenting for Malignant Superior Vena Cava Syndrome

Stenting for Malignant Superior Vena Cava Syndrome - Stenting for SVC syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000005052
Enrollment
15
Registered
2011-02-09
Start date
2011-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supra Vena Cava Syndrome

Interventions

Stenting in venous stenosis

Sponsors

Nagasaki Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. stenosis of supra or inferior vena cava with symptom 2. unable to control the symptom by drug including diuretic agents 3. adequate organ function: no heart failure, WBC≥3000/mm3, Hb≥8.0g/dl, Plt≥50000/mm3, T-Bil≤3.0mg/dl, sCr≤2.0mg/dl, ECG W.N.L, PS 0-3 4. expective to survive longer than 4 weeks 5. written informed consent

Exclusion criteria

Exclusion criteria: 1. tumor embolism in the vein 2. suspended thrombus in the peripherally stenosis 3. pulmonary embolism 4. severe cardiac dysfunction 5. both stenosis with supra and inferionr vena cava 6. with active infection 7. with acute hemorrhagic lesion 8. inadequate determinated case by attending physician

Design outcomes

Primary

MeasureTime frame
Safety—

Secondary

MeasureTime frame
Efficacy—

Countries

Japan

Contacts

Public ContactMinoru Fukuda

Nagasaki Municipal Hospital Internal Medicine

mifukuda258@nifty.com

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026